Literature DB >> 12193009

Durhamycin A, a potent inhibitor of HIV Tat transactivation.

Hiranthi Jayasuriya1, Russell B Lingham, Pia Graham, Donette Quamina, Lucia Herranz, Olga Genilloud, Magda Gagliardi, Renee Danzeisen, Joanne E Tomassini, Deborah L Zink, Ziqiang Guan, Sheo B Singh.   

Abstract

Tat is a small HIV protein essential for both viral replication and the progression of HIV disease. In our efforts to discover Tat inhibitors from natural product screening of microbial fermentation extracts, we discovered durhamycin A (1) as a potent inhibitor (IC(50) = 4.8 nM) of Tat transactivation. Detailed NMR and MS/MS studies were utilized to elucidate the structure of 1 as a new member of the aureolic acid family of antibiotics. It consists of tetrasaccharide and disaccharide moieties attached to the aglycone, which is hitherto unknown in the aureolic acid family. Three other novel analogues, durhamycin B (2), compound (3), and the aglycone (4), were also discovered or chemically prepared that were less potent than durhamycin A.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193009     DOI: 10.1021/np010642f

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  13 in total

Review 1.  Novel paradigms for drug discovery: computational multitarget screening.

Authors:  Ekachai Jenwitheesuk; Jeremy A Horst; Kasey L Rivas; Wesley C Van Voorhis; Ram Samudrala
Journal:  Trends Pharmacol Sci       Date:  2008-01-10       Impact factor: 14.819

2.  Studies on the synthesis of durhamycin A: stereoselective synthesis of a model aglycone.

Authors:  Rajan Pragani; William R Roush
Journal:  Org Lett       Date:  2008-09-23       Impact factor: 6.005

Review 3.  A comprehensive review of glycosylated bacterial natural products.

Authors:  Sherif I Elshahawi; Khaled A Shaaban; Madan K Kharel; Jon S Thorson
Journal:  Chem Soc Rev       Date:  2015-11-07       Impact factor: 54.564

4.  Structural insight into MtmC, a bifunctional ketoreductase-methyltransferase involved in the assembly of the mithramycin trisaccharide chain.

Authors:  Jhong-Min Chen; Caixia Hou; Guojun Wang; Oleg V Tsodikov; Jürgen Rohr
Journal:  Biochemistry       Date:  2015-04-07       Impact factor: 3.162

Review 5.  Advances toward Curing HIV-1 Infection in Tissue Reservoirs.

Authors:  Lisa J Henderson; Lauren B Reoma; Joseph A Kovacs; Avindra Nath
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

6.  How mithramycin stereochemistry dictates its structure and DNA binding function.

Authors:  Caixia Hou; Jürgen Rohr; Sean Parkin; Oleg V Tsodikov
Journal:  Medchemcomm       Date:  2019-03-28       Impact factor: 3.597

7.  Characterization of the terminal activation step catalyzed by oxygenase CmmOIV of the chromomycin biosynthetic pathway from Streptomyces griseus.

Authors:  Mary A Bosserman; Ana B Flórez; Khaled A Shaaban; Alfredo F Braña; Jose A Salas; Carmen Méndez; Jürgen Rohr
Journal:  Biochemistry       Date:  2011-02-02       Impact factor: 3.162

8.  Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis.

Authors:  Lily L Remsing; Ana M González; Mohammad Nur-e-Alam; M José Fernández-Lozano; Alfredo F Braña; Uwe Rix; Marcos A Oliveira; Carmen Méndez; José A Salas; Jürgen Rohr
Journal:  J Am Chem Soc       Date:  2003-05-14       Impact factor: 15.419

9.  Identification of Aristolactam Derivatives That Act as Inhibitors of Human Immunodeficiency Virus Type 1 Infection and Replication by Targeting Tat-Mediated Viral Transcription.

Authors:  YoungHyun Shin; Chul Min Park; Hong Gi Kim; Dong-Eun Kim; Min Suk Choi; Jeong-Ah Kim; Byeong-Sun Choi; Cheol-Hee Yoon
Journal:  Virol Sin       Date:  2020-08-10       Impact factor: 4.327

Review 10.  Role of Tat protein in HIV neuropathogenesis.

Authors:  Wenxue Li; Guanhan Li; Joseph Steiner; Avindra Nath
Journal:  Neurotox Res       Date:  2009-03-21       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.